About
Nyxoah is a Belgian medical technology company focused on addressing Obstructive Sleep Apnea (OSA), the world's most prevalent sleep-disordered breathing condition, which affects approximately 936 million people globally between the ages of 30 and 69. Nyxoah's lead solution is the Genio® system — a breakthrough, patient-centered hypoglossal neurostimulation therapy that is both leadless and battery-free, setting it apart from traditional OSA interventions. The Genio® system is designed for patients who suffer from moderate to severe OSA (AHI of 15 to 65), have not tolerated, failed, or refused PAP (Positive Airway Pressure) therapy, and are not significantly overweight. By stimulating the hypoglossal nerve, the device keeps the airway open during sleep, reducing apnea episodes and improving patient outcomes. Untreated OSA is associated with significantly elevated mortality risk, a twofold increased risk of stroke, a fivefold increased risk of cardiovascular mortality, and a 140% increased risk of heart failure. Nyxoah's technology offers a clinically validated alternative for patients who need an effective, implantable solution. The company is headquartered in Mont-Saint-Guibert, Belgium, and is actively expanding its team of medical and engineering professionals. Nyxoah targets clinicians, sleep medicine specialists, and healthcare institutions seeking advanced neurostimulation therapies for OSA management.
Key Features
- Leadless & Battery-Free Design: The Genio® system is a unique, implantable device that requires no leads or internal battery, simplifying the patient experience and reducing maintenance concerns.
- Hypoglossal Nerve Stimulation: Targets the hypoglossal nerve to keep the upper airway open during sleep, directly addressing the root cause of OSA.
- Patient-Centered Therapy: Designed for patients with moderate to severe OSA who have failed or are intolerant of traditional PAP therapy, offering a personalized alternative treatment path.
- Clinically Validated Outcomes: Supported by clinical studies demonstrating significant reductions in apnea episodes and improved cardiovascular risk profiles for treated patients.
Use Cases
- Treating moderate to severe Obstructive Sleep Apnea in patients who have failed or are intolerant of CPAP/PAP therapy
- Providing a minimally complex implantable alternative for sleep medicine specialists managing refractory OSA cases
- Reducing cardiovascular risk in OSA patients through effective long-term airway management during sleep
- Offering a battery-free neurostimulation solution for healthcare institutions seeking advanced OSA interventions
- Supporting clinical research into hypoglossal nerve stimulation outcomes and OSA comorbidity reduction
Pros
- No Battery or Leads Required: The innovative leadless, battery-free design reduces device complexity, surgical burden, and long-term maintenance for patients and clinicians.
- Alternative to PAP Therapy: Provides an effective implantable option for the large population of OSA patients who cannot tolerate or have failed CPAP/BiPAP treatments.
- Strong Clinical Evidence: Backed by peer-reviewed clinical data demonstrating meaningful improvements in AHI and associated cardiovascular risk reduction.
Cons
- Requires Surgical Implantation: As an implantable medical device, the Genio® system necessitates a surgical procedure, which carries inherent risks and is not suitable for all patients.
- Not Available in All Markets: The device is not yet approved for sale in the United States and may have limited availability in certain regions.
- Strict Patient Eligibility Criteria: Only suitable for patients with moderate to severe OSA (AHI 15–65) who are not significantly overweight and have failed PAP therapy.
Frequently Asked Questions
What is the Genio® system?
The Genio® system is Nyxoah's lead medical device — a leadless, battery-free hypoglossal neurostimulation implant designed to treat moderate to severe Obstructive Sleep Apnea by stimulating the hypoglossal nerve to maintain an open airway during sleep.
Who is eligible for the Genio® system?
The Genio® system is intended for patients with moderate to severe OSA (an AHI of 15 to 65) who have not tolerated, failed, or refused PAP therapy and are not significantly overweight.
Is the Genio® system available in the United States?
As of the latest published information, the Genio® system is not approved for sale in the United States. Availability varies by region.
How does untreated OSA affect health?
Untreated OSA is associated with a significantly increased mortality risk, a twofold greater risk of stroke, a fivefold greater risk of cardiovascular mortality, and a 140% increased risk of heart failure.
How can I join the Nyxoah team?
Nyxoah is actively hiring motivated professionals. Interested candidates can submit their CV and application to [email protected].
